Análisis de la acción Tenaya Therapeutics Inc (TNYA)

Análisis de IA of Tenaya Therapeutics Inc (TNYA)

Vender

Tenaya Therapeutics Inc is not a good buy right now. The stock is currently trading at $0.361, which is very close to its 52-week low of $0.36. The RSI is at a low 23.328, indicating that the stock is oversold, but this could also suggest a continued downward trend. Additionally, the company has reported significant losses, with a net income loss of $43,393,000 in Q2 2026, and a gross margin of only 100% in the most recent quarters, which is not sustainable. The stock has declined 73.84% over the past year, and insider selling has increased by 55,373.56% in the last month, indicating a lack of confidence from those within the company. The main risk is the company's ongoing financial losses and the potential for further declines in stock price.

Métricas de valoración

El PER previsto actual de Tenaya Therapeutics Inc (TNYA) es 0.00, frente a su media de 5 años de -2.21.

PER previsto

Sobrevalorado

Media 5A P/E

-2.21

P/E actual

0.00

Sobrevalorada

-0.79

Infravalorada

-3.63

EV/EBITDA previsto

Valor razonable

Media 5A EV/EBITDA

-1.15

EV/EBITDA actual

-0.49

Sobrevalorada

0.41

Infravalorada

-2.70

Precio/ventas previsto

Valor razonable

Media 5A P/S

65.91

P/S actual

33.72

Sobrevalorada

203.26

Infravalorada

-71.43

Escenarios de precio de Alphio AI para TNYA

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%TNYA

$1.05

Precio del escenario

B

Base

Base · 50%TNYA

$0.92

Precio del escenario

B

Bajista

Bajista · 25%TNYA

$0.82

Precio del escenario

Ballenas con TNYA en cartera

C

Casdin Capital, LLC

+ Con en carteraTNYA

+3.80%

Rentabilidad a 3 meses

S

StepStone Group Inc.

+ Con en carteraTNYA

-0.27%

Rentabilidad a 3 meses

Preguntas frecuentes sobre TNYA, respondidas por Alphio AI

Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. Its pipeline includes TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a working MYBPC3 gene to heart muscle cells via a single intravenous infusion, increasing MyBP-C protein levels to address the underlying cause of MYBPC3-associated HCM with the aim of halting or even reversing disease after a single dose. Its MyPEAK-1 Phase I b/2 clinical trial is an ongoing, multi-center, open-label, dose-escalating study designed to assess the safety, tolerability and clinical efficacy of a one-time intravenous infusion of TN-201 gene replacement therapy. TN-401 is its AAV9-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Tenaya Therapeutics Inc is not a good buy right now. The stock is currently trading at $0.361, which is very close to its 52-week low of $0.36. The RSI is at a low 23.328, indicating that the stock is oversold, but this could also suggest a continued downward trend. Additionally, the company has reported significant losses, with a net income loss of $43,393,000 in Q2 2026, and a gross margin of only 100% in the most recent quarters, which is not sustainable. The stock has declined 73.84% over the past year, and insider selling has increased by 55,373.56% in the last month, indicating a lack of confidence from those within the company. The main risk is the company's ongoing financial losses and the potential for further declines in stock price.